Search

Your search keyword '"Naleway, Allison L."' showing total 759 results
Start Over Author "Naleway, Allison L."
759 results on '"Naleway, Allison L."'

1. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines

Author

Liu, Feng, Gross, F. Liaini, Joshi, Sneha, Gaglani, Manjusha, Naleway, Allison L., Murthy, Kempapura, Groom, Holly C., Wesley, Meredith G., Edwards, Laura J., Grant, Lauren, Kim, Sara S., Sambhara, Suryaprakash, Gangappa, Shivaprakash, Tumpey, Terrence, Thompson, Mark G., Fry, Alicia M., Flannery, Brendan, Dawood, Fatimah S., and Levine, Min Z.

Published
2024
Full Text
View/download PDF

2. Patient and Epidemiological Factors Associated With Influenza Testing in Hospitalized Adults With Acute Respiratory Illnesses, 2016-2017 to 2019-2020.

Author

Dalton, Alexandra F, Couture, Alexia, DeSilva, Malini B, Irving, Stephanie A, Gohil, Shruti, Rao, Suchitra, Fink, Rebecca V, Naleway, Allison L, Guo, Zijing, Sundaresan, Devi, Birch, Rebecca J, Ball, Sarah, Zheng, Kai, Ong, Toan C, Reed, Carrie, and Bozio, Catherine H

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Influenza, Infectious Diseases, Clinical Research, Health Services, Prevention, Lung, Rare Diseases, Pneumonia & Influenza, Infection, Good Health and Well Being, acute respiratory illness, clinical testing, hospitalization, influenza, Clinical sciences, Medical microbiology
Abstract

BackgroundData are limited on influenza testing among adults with acute respiratory illness (ARI)-associated hospitalizations. We identified factors associated with influenza testing in adult ARI-associated hospitalizations across the 2016-2017 through 2019-2020 influenza seasons.MethodsUsing data from 4 health systems in the United States, we identified hospitalizations that had an ARI discharge diagnosis or respiratory virus test. A hospitalization with influenza testing was based on testing performed within 14 days before through 72 hours after admission. We used random forest analysis to identify patient characteristics and influenza activity indicators that were most important in terms of their relationship to influenza testing.ResultsAcross 4 seasons, testing rates ranged from 14.8%-19.4% at 3 pooled sites and 60.1%-78.5% at a fourth site with different testing practices. Discharge diagnoses of pneumonia or infectious disease of noninfluenza etiology, presence of ARI signs/symptoms, hospital admission month, and influenza-like illness activity level were consistently among the variables with the greatest relative importance.ConclusionsSelect ARI diagnoses and indicators of influenza activity were the most important factors associated with influenza testing among ARI-associated hospitalizations. Improved understanding of which patients are tested may enhance influenza burden estimates and allow for more timely clinical management of influenza-associated hospitalizations.

Published
2023

3. Relative Risks of COVID-19–Associated Hospitalizations and Clinical Outcomes by Age and Race/Ethnicity—March 2020–March 2021

Author

Bozio, Catherine H, Butterfield, Kristen, Irving, Stephanie A, Vazquez-Benitez, Gabriela, Ong, Toan C, Zheng, Kai, Ball, Sarah W, Naleway, Allison L, Barron, Michelle, and Reed, Carrie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lung, Clinical Research, Prevention, Cardiovascular, Patient Safety, Respiratory, Good Health and Well Being, COVID-19, adults, hospitalization, race, ethnicity, race/ethnicity, Clinical sciences, Medical microbiology
Abstract

BackgroundLimited data exist on population-based risks and risk ratios (RRs) of coronavirus disease 2019 (COVID-19)-associated hospitalizations and clinical outcomes stratified by age and race/ethnicity.MethodsUsing data from electronic health records and claims from 4 US health systems for the period March 2020-March 2021, we calculated risk and RR by age and race/ethnicity for COVID-19-associated hospitalizations and clinical outcomes among adults (≥18 years). COVID-19-associated hospitalizations were defined based on COVID-19 discharge codes or a positive severe acute respiratory syndrome coronavirus 2 result. Proportions of acute exacerbations of underlying conditions were estimated among hospitalized patients with select underlying conditions, stratified by age and race/ethnicity.ResultsAmong 2.6 million adults included in the patient cohort, 6879 had COVID-19-associated hospitalizations during March 2020-March 2021 (risk: 264 per 100 000 population). Compared with younger, non-Hispanic White adults, non-Hispanic Black and Hispanic adults aged ≥65 years had the highest hospitalization risk ratios (RR, 8.6; 95% CI, 7.6-9.9; and RR, 9.3; 95% CI, 8.5-10.3, respectively). Among hospitalized adults with COVID-19 and renal disease or cardiovascular disease, the highest proportion of acute renal failure (55.5%) or congestive heart failure (43.9%) occurred in older, non-Hispanic Black patients. Among hospitalized adults with chronic lung disease or asthma, the highest proportion of respiratory failure (62.9%) or asthma exacerbation (66.7%) occurred in older, Hispanic patients.ConclusionsDuring the first year of the US COVID-19 pandemic in this cohort, older non-Hispanic Black and Hispanic adults had the highest relative risks of COVID-19-associated hospitalization and adverse outcomes and, among those with select underlying conditions, the highest occurrences of acute exacerbations of underlying conditions.

Published
2022

6. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

Author

Ellingson, Katherine D., Hollister, James, Porter, Cynthia J., Khan, Sana M., Feldstein, Leora R., Naleway, Allison L., Gaglani, Manjusha, Caban-Martinez, Alberto J., Tyner, Harmony L., Lowe, Ashley A., Olsho, Lauren E.W., Meece, Jennifer, Yoon, Sarang K., Mak, Josephine, Kuntz, Jennifer L., Solle, Natasha Schaefer, Respet, Karley, Baccam, Zoe, Wesley, Meredith G., Thiese, Matthew S., Yoo, Young M., Odean, Marilyn J., Miiro, Flavia N., Pickett, Steve L., Phillips, Andrew L., Grant, Lauren, Romine, James K., Herring, Meghan K., Hegmann, Kurt T., Lamberte, Julie Mayo, Sokol, Brian, Jovel, Krystal S., Thompson, Mark G., Rivers, Patrick, Pilishvili, Tamara, Lutrick, Karen, Burgess, Jefferey L., Midgley, Claire M., and Fowlkes, Ashley L.

Subjects
Diseases -- Relapse, Medical personnel -- Statistics -- Health aspects, Health
Abstract

Essential and frontline workers experience repeated occupational exposure to SARS-CoV-2 (1). The variant B.1.1.529 (Omicron) is characterized by unprecedented transmissibility and potential for immune evasion, which led to a surge [...]

Published
2023
Full Text
View/download PDF

7. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

Author

Hollister, James, Caban-Martinez, Alberto J., Ellingson, Katherine D., Beitel, Shawn, Fowlkes, Ashley L., Lutrick, Karen, Tyner, Harmony L., Naleway, Allison L., Yoon, Sarang K., Gaglani, Manjusha, Hunt, Danielle, Meece, Jennifer, Mayo Lamberte, Julie, Schaefer Solle, Natasha, Rose, Spencer, Dunnigan, Kayan, Khan, Sana M., Kuntz, Jennifer L., Fisher, Julia M., Coleman, Alissa, Britton, Amadea, Thiese, Matthew S., Hegmann, Kurt T., Pavuk, Marian, Ramadan, Ferris A., Fuller, Sammantha, Nematollahi, Amy, Sprissler, Ryan, and Burgess, Jefferey L.

Published
2023
Full Text
View/download PDF

8. Racial and ethnic disparities in influenza vaccination coverage among pregnant women in the United States: The contribution of vaccine-related attitudes

Author

Daley, Matthew F., Reifler, Liza M., Shoup, Jo Ann, Glanz, Jason M., Naleway, Allison L., Nelson, Jennifer C., Williams, Joshua T.B., McLean, Huong Q., Vazquez-Benitez, Gabriela, Goddard, Kristin, Lewin, Bruno J., Weintraub, Eric S., McNeil, Michael M., Razzaghi, Hilda, and Singleton, James A.

Published
2023
Full Text
View/download PDF

10. Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

Author

Adams, Katherine, Riddles, John J., Rowley, Elizabeth A.K., Grannis, Shaun J., Gaglani, Manjusha, Fireman, Bruce, Hartmann, Emily, Naleway, Allison L., Stenehjem, Edward, Hughes, Alexandria, Dalton, Alexandra F., Natarajan, Karthik, Dascomb, Kristin, Raiyani, Chandni, Irving, Stephanie A., Sloan-Aagard, Chantel, Kharbanda, Anupam B., DeSilva, Malini B., Dixon, Brian E., Ong, Toan C., Keller, Jean, Dickerson, Monica, Grisel, Nancy, Murthy, Kempapura, Nanez, Juan, Fadel, William F., Ball, Sarah W., Patel, Palak, Arndorfer, Julie, Mamawala, Mufaddal, Valvi, Nimish R., Dunne, Margaret M., Griggs, Eric P., Embi, Peter J., Thompson, Mark G., Link-Gelles, Ruth, and Tenforde, Mark W.

Published
2023
Full Text
View/download PDF

11. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged [greater than or equal to]18 Years with Immunocompromising Conditions--VISION Network, September 2023-February 2024

Author

Link-Gelles, Ruth, Rowley, Elizabeth A.K., DeSilva, Malini B., Dascomb, Kristin, Irving, Stephanie A., Klein, Nicola P., Grannis, Shaun J., Ong, Toan C., Weber, Zachary A., Fleming-Dutra, Katherine E., McEvoy, Charlene E., Akinsete, Omobosola, Bride, Daniel, Sheffield, Tamara, Naleway, Allison L., Zerbo, Ousseny, Fireman, Bruce, Hansen, John, Goddard, Kristin, Dixon, Brian E., Rogerson, Colin, Fadel, William F., Duszynski, Thomas, Rao, Suchitra, Barron, Michelle A., Reese, Sarah E., Ball, Sarah W., Dunne, Margaret M., Natarajan, Karthik, Okwuazi, Erica, Shah, Ami B., Wiegand, Ryan, Tenforde, Mark W., and Payne, Amanda B.

Subjects
Vaccination, Adults, Vaccines, Health
Abstract

Introduction On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 COVID-19 vaccination with a monovalent XBB.1.5--derived vaccine for all persons aged [greater than or equal to]6 [...]

Published
2024

12. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged [greater than or equal to]18 Years--VISION and IVY Networks, September 2023- January 2024

Author

DeCuir, Jennifer, Payne, Amanda B., Self, Wesley H., Rowley, Elizabeth A.K., Dascomb, Kristin, DeSilva, Malini B., Irving, Stephanie A., Grannis, Shaun J., Ong, Toan C., Klein, Nicola P., Weber, Zachary A., Reese, Sarah E., Ball, Sarah W., Barron, Michelle A., Naleway, Allison L., Dixon, Brian E., Essien, Inih, Bride, Daniel, Natarajan, Karthik, Fireman, Bruce, Shah, Ami B., Okwuazi, Erica, Wiegand, Ryan, Zhu, Yuwei, Lauring, Adam S., Martin, Emily T., Gaglani, Manjusha, Peltan, Ithan D., Brown, Samuel M., Ginde, Adit A., Mohr, Nicholas M., Gibbs, Kevin W., Hager, David N., Prekker, Matthew, Mohamed, Amira, Srinivasan, Vasisht, Steingrub, Jay S., Khan, Akram, Busse, Laurence W., Duggal, Abhijit, Wilson, Jennifer G., Chang, Steven Y., Mallow, Christopher, Kwon, Jennie H., Exline, Matthew C., Columbus, Cristie, Vaughn, Ivana A., Safdar, Basmah, Mosier, Jarrod M., Harris, Estelle S., Casey, Jonathan D., Chappell, James D., Grijalva, Carlos G., Swan, Sydney A., Johnson, Cassandra, Lewis, Nathaniel M., Ellington, Sascha, Adams, Katherine, Tenforde, Mark W., Paden, Clinton R., Dawood, Fatimah S., Fleming-Dutra, Katherine E., Surie, Diya, and Link-Gelles, Ruth

Subjects
Vaccination, Medical research, Medicine, Experimental, Hospitals -- Emergency service, Emergency medicine, Adults, Vaccines, Health, Vanderbilt University. Medical Center
Abstract

Introduction On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 COVID-19 vaccination with a monovalent XBB.1.5--derived vaccine for all persons aged [greater than or equal to]6 [...]

Published
2024

13. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Author

Embi, Peter J., Levy, Matthew E., Patel, Palak, DeSilva, Malini B., Gaglani, Manjusha, Dascomb, Kristin, Dunne, Margaret M., Klein, Nicola P., Ong, Toan C., Grannis, Shaun J., Natarajan, Karthik, Yang, Duck-Hye, Stenehjem, Edward, Zerbo, Ousseny, McEvoy, Charlene, Rao, Suchitra, Thompson, Mark G., Konatham, Deepika, Irving, Stephanie A., Dixon, Brian E., Han, Jungmi, Schrader, Kristin E., Grisel, Nancy, Lewis, Ned, Kharbanda, Anupam B., Barron, Michelle A., Reynolds, Sue, Liao, I-Chia, Fadel, William F., Rowley, Elizabeth A., Arndorfer, Julie, Goddard, Kristin, Murthy, Kempapura, Valvi, Nimish R., Weber, Zachary A., Fireman, Bruce, Reese, Sarah E., Ball, Sarah W., and Naleway, Allison L.

Published
2023
Full Text
View/download PDF

14. Abnormal uterine bleeding diagnoses and care following COVID-19 vaccination

Author

DeNoble, Anna E., DeSilva, Malini, Ellington, Sascha, Henninger, Michelle, Jazwa, Amelia, Kharbanda, Elyse, Lipkind, Heather, Malden, Debbie, McNeil, Michael M., Tartof, Sara, Zerbo, Ousseny, Brooks, Neon, Irving, Stephanie A., Kauffman, Tia L., Vesco, Kimberly K., Slaughter, Matthew, Smith, Ning, Tepper, Naomi K., Olson, Christine K., Weintraub, Eric S., and Naleway, Allison L.

Published
2024
Full Text
View/download PDF

15. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

Author

Embi, Peter J., Levy, Matthew E., Naleway, Allison L., Patel, Palak, Gaglani, Manjusha, Natarajan, Karthik, Dascomb, Kristin, Ong, Toan C., Klein, Nicola P., Liao, I-Chia, Grannis, Shaun J., Han, Jungmi, Stenehjem, Edward, Dunne, Margaret M., Lewis, Ned, Irving, Stephanie A., Rao, Suchitra, McEvoy, Charlene, Bozio, Catherine H., Murthy, Kempapura, Dixon, Brian E., Grisel, Nancy, Yang, Duck-Hye, Goddard, Kristin, Kharbanda, Anupam B., Reynolds, Sue, Raiyani, Chandni, Fadel, William F., Arndorfer, Julie, Rowley, Elizabeth A., Fireman, Bruce, Ferdinands, Jill, Valvi, Nimish R., Ball, Sarah W., Zerbo, Ousseny, Griggs, Eric P., Mitchell, Patrick K., Porter, Rachael M., Kiduko, Salome A., Blanton, Lenee, Zhuang, Yan, Steffens, Andrea, Reese, Sarah E., Olson, Natalie, Williams, Jeremiah, Dickerson, Monica, McMorrow, Meredith, Schrag, Stephanie J., Verani, Jennifer R., Fry, Alicia M., Azziz-Baumgartner, Eduardo, Barron, Michelle A., Thompson, Mark G., and DeSilva, Malini B.

Published
2022
Full Text
View/download PDF

16. Incidence Rates of Medically Attended COVID-19 in Infants Less Than 6 Months of Age

Author

Griffin, Isabel, Irving, Stephanie A., Arriola, Carmen Sofia, Campbell, Angela P., Li, De-Kun, Dawood, Fatimah S., Doughty-Skierski, Caroline, Ferber, Jeannette R., Ferguson, Nickolas, Hadden, Louise, Henderson, Jillian T., Juergens, Mary, Kancharla, Venkatesh, Naleway, Allison L., Newes-Adeyi, Gabriella, Nicholson, Erin, Odouli, Roxana, Reichle, Lawrence, Sanyang, Mo, Woodworth, Kate, and Munoz, Flor M.

Published
2023
Full Text
View/download PDF

17. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination

Author

Vesco, Kimberly K., primary, Denoble, Anna E., additional, Lipkind, Heather S., additional, Kharbanda, Elyse O., additional, DeSilva, Malini B., additional, Daley, Matthew F., additional, Getahun, Darios, additional, Zerbo, Ousseny, additional, Naleway, Allison L., additional, Jackson, Lisa, additional, Williams, Joshua T.B., additional, Boyce, Thomas G., additional, Fuller, Candace C., additional, Weintraub, Eric S., additional, and Vazquez-Benitez, Gabriela, additional

Published
2024
Full Text
View/download PDF

18. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024

Author

Link-Gelles, Ruth, primary, Rowley, Elizabeth A.K., additional, DeSilva, Malini B., additional, Dascomb, Kristin, additional, Irving, Stephanie A., additional, Klein, Nicola P., additional, Grannis, Shaun J., additional, Ong, Toan C., additional, Weber, Zachary A., additional, Fleming-Dutra, Katherine E., additional, McEvoy, Charlene E., additional, Akinsete, Omobosola, additional, Bride, Daniel, additional, Sheffield, Tamara, additional, Naleway, Allison L., additional, Zerbo, Ousseny, additional, Fireman, Bruce, additional, Hansen, John, additional, Goddard, Kristin, additional, Dixon, Brian E., additional, Rogerson, Colin, additional, Fadel, William F., additional, Duszynski, Thomas, additional, Rao, Suchitra, additional, Barron, Michelle A., additional, Reese, Sarah E., additional, Ball, Sarah W., additional, Dunne, Margaret M., additional, Natarajan, Karthik, additional, Okwuazi, Erica, additional, Shah, Ami B., additional, Wiegand, Ryan, additional, Tenforde, Mark W., additional, and Payne, Amanda B., additional

Published
2024
Full Text
View/download PDF

21. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Author

Feldstein, Leora R., primary, Britton, Amadea, additional, Grant, Lauren, additional, Wiegand, Ryan, additional, Ruffin, Jasmine, additional, Babu, Tara M., additional, Briggs Hagen, Melissa, additional, Burgess, Jefferey L., additional, Caban-Martinez, Alberto J., additional, Chu, Helen Y., additional, Ellingson, Katherine D., additional, Englund, Janet A., additional, Hegmann, Kurt T., additional, Jeddy, Zuha, additional, Lauring, Adam S., additional, Lutrick, Karen, additional, Martin, Emily T., additional, Mathenge, Clare, additional, Meece, Jennifer, additional, Midgley, Claire M., additional, Monto, Arnold S., additional, Newes-Adeyi, Gabriella, additional, Odame-Bamfo, Leah, additional, Olsho, Lauren E. W., additional, Phillips, Andrew L., additional, Rai, Ramona P., additional, Saydah, Sharon, additional, Smith, Ning, additional, Steinhardt, Laura, additional, Tyner, Harmony, additional, Vandermeer, Meredith, additional, Vaughan, Molly, additional, Yoon, Sarang K., additional, Gaglani, Manjusha, additional, and Naleway, Allison L., additional

Published
2024
Full Text
View/download PDF

23. Postmenopausal bleeding after COVID-19 vaccination

Author

Crane, Brad, Mittendorf, Kathleen F., Burch, Debra, DeSilva, Malini, Ellington, Sascha, Henninger, Michelle, Jazwa, Amelia, Kharbanda, Elyse, Lipkind, Heather, Malden, Debbie, McNeil, ; Michael M., Suh-Burgmann, Betty, Tartof, Sara, Zerbo, Ousseny, Kauffman, Tia L., Irving, Stephanie A., Brooks, Neon, Vesco, Kimberly K., Slaughter, Matthew, Smith, Ning, Tepper, Naomi K., Olson, Christine K., Weintraub, Eric S., and Naleway, Allison L.

Published
2024
Full Text
View/download PDF

24. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023.

Author

Tenforde, Mark W, Weber, Zachary A, Yang, Duck-Hye, DeSilva, Malini B, Dascomb, Kristin, Irving, Stephanie A, Naleway, Allison L, Gaglani, Manjusha, Fireman, Bruce, Lewis, Ned, Zerbo, Ousseny, Goddard, Kristin, Timbol, Julius, Hansen, John R, Grisel, Nancy, Arndorfer, Julie, McEvoy, Charlene E, Essien, Inih J, Rao, Suchitra, and Grannis, Shaun J

Subjects
FLU vaccine efficacy, SEASONAL influenza, VACCINE effectiveness, INFLUENZA vaccines, INFLUENZA
Abstract

Background The 2022–2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed. Methods Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022–2023 season against influenza A–associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights. Results The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A–associated ED/UC encounters was 44% (95% confidence interval [CI], 40%–47%) overall and 45% and 41% among adults aged 18–64 and ≥65 years, respectively. VE against influenza A–associated hospitalizations was 35% (95% CI, 27%–43%) overall and 23% and 41% among adults aged 18–64 and ≥65 years, respectively. Conclusions VE was moderate during the 2022–2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Postmenopausal bleeding after COVID-19 vaccination

Author

Kauffman, Tia L., primary, Irving, Stephanie A., additional, Brooks, Neon, additional, Vesco, Kimberly K., additional, Slaughter, Matthew, additional, Smith, Ning, additional, Tepper, Naomi K., additional, Olson, Christine K., additional, Weintraub, Eric S., additional, Naleway, Allison L., additional, Crane, Brad, additional, Mittendorf, Kathleen F., additional, Burch, Debra, additional, DeSilva, Malini, additional, Ellington, Sascha, additional, Henninger, Michelle, additional, Jazwa, Amelia, additional, Kharbanda, Elyse, additional, Lipkind, Heather, additional, Malden, Debbie, additional, McNeil, ; Michael M., additional, Suh-Burgmann, Betty, additional, Tartof, Sara, additional, and Zerbo, Ousseny, additional

Published
2024
Full Text
View/download PDF

26. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023

Author

Tenforde, Mark W, primary, Weber, Zachary A, additional, Yang, Duck-Hye, additional, DeSilva, Malini B, additional, Dascomb, Kristin, additional, Irving, Stephanie A, additional, Naleway, Allison L, additional, Gaglani, Manjusha, additional, Fireman, Bruce, additional, Lewis, Ned, additional, Zerbo, Ousseny, additional, Goddard, Kristin, additional, Timbol, Julius, additional, Hansen, John R, additional, Grisel, Nancy, additional, Arndorfer, Julie, additional, McEvoy, Charlene E, additional, Essien, Inih J, additional, Rao, Suchitra, additional, Grannis, Shaun J, additional, Kharbanda, Anupam B, additional, Natarajan, Karthik, additional, Ong, Toan C, additional, Embi, Peter J, additional, Ball, Sarah W, additional, Dunne, Margaret M, additional, Kirshner, Lindsey, additional, Wiegand, Ryan E, additional, Dickerson, Monica, additional, Patel, Palak, additional, Ray, Caitlin, additional, Flannery, Brendan, additional, Garg, Shikha, additional, Adams, Katherine, additional, and Klein, Nicola P, additional

Published
2023
Full Text
View/download PDF

27. 1163. Influenza Vaccination Coverage through December among Persons Ages Six Months and Older in the Vaccine Safety Datalink, 2017-18 through 2022-23 Influenza Seasons

Author

Irving, Stephanie, primary, Groom, Holly C, additional, Belongia, Edward, additional, Crane, Bradley, additional, Daley, Matthew F, additional, Goddard, Kristin, additional, Jackson, Lisa, additional, Kenigsberg, Tat’Yana A, additional, Kuckler, Leslie, additional, Naleway, Allison L, additional, Patel, Suchita A, additional, Tseng, Hung Fu, additional, Williams, Joshua T B, additional, and Weintraub, Eric, additional

Published
2023
Full Text
View/download PDF

28. 2082. Effectiveness of Bivalent mRNA Vaccines in Preventing SARS-CoV-2 Infection Among Children Aged 5-17 years: an Evaluation of Multicenter Prospective Cohorts, United States, September 2022 - January 2023

Author

Feldstein, Leora R, primary, Britton, Amadea, additional, Beacham, Lauren, additional, Wiegand, Ryan E, additional, Ruffin, Jasmine, additional, Briggs-Hagen, Melissa, additional, Fowlkes, Ashley, additional, Burgess, Jefferey L, additional, Caban-Martinez, Alberto, additional, Chu, Helen Y, additional, Englund, Janet A, additional, Hegmann, Kurt, additional, Jeddy, Zuha, additional, Lutrick, Karen, additional, Martin, Emily T, additional, Meece, Jennifer K, additional, Midgley, Claire, additional, Monto, Arnold, additional, Newes-Adeyi, Gabriella, additional, Odame-Bamfo, Leah, additional, Olsho, Lauren E W, additional, Saydah, Sharon, additional, Smith, Ning, additional, Steinhardt, Laura, additional, Tyner, Harmony, additional, Yoon, Sarang K, additional, Gaglani, Manjusha, additional, and Naleway, Allison L, additional

Published
2023
Full Text
View/download PDF

29. 1162. Influenza Vaccination Among Pregnant People in the Vaccine Safety Datalink, 2016-17 through 2022-23 Influenza Seasons

Author

Irving, Stephanie, primary, Crane, Bradley, additional, Weintraub, Eric, additional, Kauffman, Tia L, additional, Brooks, Neon, additional, Patel, Suchita A, additional, Razzaghi, Hilda, additional, Belongia, Edward, additional, Daley, Matthew F, additional, Getahun, Darios, additional, Glenn, Sungching C, additional, Hambidge, Simon, additional, Jackson, Lisa, additional, Kharbanda, Elyse, additional, Klein, Nicola P, additional, Zerbo, Ousseny, additional, and Naleway, Allison L, additional

Published
2023
Full Text
View/download PDF

31. 1836. Disparities in COVID-19 Vaccination Coverage Among a Large Patient Population in a Network of Community-Based Healthcare Organizations

Author

Groom, Holly C, primary, Biel, Frances, additional, Crane, Bradley, additional, Sun, Evelyn, additional, Georgescu, Joanna, additional, Weintraub, Eric, additional, McNeil, Michael, additional, Jazwa, Amelia, additional, Owens, Constance, additional, Naleway, Allison L, additional, and Schmidt, Teresa, additional

Published
2023
Full Text
View/download PDF

32. Vaccine Effectiveness Against Pediatric Influenza-A–Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022–2023 Season: VISION Network

Author

Adams, Katherine, primary, Weber, Zachary A, additional, Yang, Duck-Hye, additional, Klein, Nicola P, additional, DeSilva, Malini B, additional, Dascomb, Kristin, additional, Irving, Stephanie A, additional, Naleway, Allison L, additional, Rao, Suchitra, additional, Gaglani, Manjusha, additional, Flannery, Brendan, additional, Garg, Shikha, additional, Kharbanda, Anupam B, additional, Grannis, Shaun J, additional, Ong, Toan C, additional, Embi, Peter J, additional, Natarajan, Karthik, additional, Fireman, Bruce, additional, Zerbo, Ousseny, additional, Goddard, Kristin, additional, Timbol, Julius, additional, Hansen, John R, additional, Grisel, Nancy, additional, Arndorfer, Julie, additional, Ball, Sarah W, additional, Dunne, Margaret M, additional, Kirshner, Lindsey, additional, Chung, Jessie R, additional, and Tenforde, Mark W, additional

Published
2023
Full Text
View/download PDF

33. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design

Author

Payne, Amanda B., primary, Ciesla, Allison Avrich, additional, Rowley, Elizabeth A.K., additional, Weber, Zachary A., additional, Reese, Sarah E., additional, Ong, Toan C., additional, Vazquez-Benitez, Gabriela, additional, Naleway, Allison L., additional, Klein, Nicola P, additional, Embi, Peter J., additional, Grannis, Shaun J., additional, Kharbanda, Anupam B., additional, Gaglani, Manjusha, additional, Tenforde, Mark W., additional, and Link-Gelles, Ruth, additional

Published
2023
Full Text
View/download PDF

34. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19--Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions--VISION Network, September 2022-April 2023

Author

Link-Gelles, Ruth, Weber, Zachary A., Reese, Sarah E., Payne, Amanda B., Gaglani, Manjusha, Adams, Katherine, Kharbanda, Anupam B., Natarajan, Karthik, DeSilva, Malini B., Dascomb, Kristin, Irving, Stephanie A., Klein, Nicola P., Grannis, Shaun J., Ong, Toan C., Embi, Peter J., Dunne, Margaret M., Dickerson, Monica, McEvoy, Charlene, Arndorfer, Julie, Naleway, Allison L., Goddard, Kristin, Dixon, Brian E., Griggs, Eric P., Hansen, John, Valvi, Nimish, Najdowski, Morgan, Timbol, Julius, Rogerson, Colin, Fireman, Bruce, Fadel, William F., Patel, Palak, Ray, Caitlin S., Wiegand, Ryan, Ball, Sarah, and Tenforde, Mark W.

Subjects
Medical research, Medicine, Experimental, Messenger RNA, Emergency medicine, Adults, Vaccines, Health
Abstract

On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged [greater than or equal to] 12 years who [...]

Published
2023

35. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions -- VISION Network, September 2023-February 2024.

Author

Link-Gelles, Ruth, Rowley, Elizabeth A. K., DeSilva, Malini B., Dascomb, Kristin, Irving, Stephanie A., Klein, Nicola P., Grannis, Shaun J., Ong, Toan C., Weber, Zachary A., Fleming-Dutra, Katherine E., McEvoy, Charlene E., Akinsete, Omobosola, Bride, Daniel, Sheffield, Tamara, Naleway, Allison L., Zerbo, Ousseny, Fireman, Bruce, Hansen, John, Goddard, Kristin, and Dixon, Brian E.

Subjects
COVID-19 vaccines, HOSPITAL care, IMMUNOCOMPROMISED patients, VACCINATION
Abstract

In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged =6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged =18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged =6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses =2 months after the last recommended COVID-19 vaccine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Vaccine Effectiveness Against Pediatric Influenza-A–Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022–2023 Season: VISION Network.

Author

Adams, Katherine, Weber, Zachary A, Yang, Duck-Hye, Klein, Nicola P, DeSilva, Malini B, Dascomb, Kristin, Irving, Stephanie A, Naleway, Allison L, Rao, Suchitra, Gaglani, Manjusha, Flannery, Brendan, Garg, Shikha, Kharbanda, Anupam B, Grannis, Shaun J, Ong, Toan C, Embi, Peter J, Natarajan, Karthik, Fireman, Bruce, Zerbo, Ousseny, and Goddard, Kristin

Subjects
MEDICAL care use, IMMUNIZATION, RESEARCH funding, INTERPROFESSIONAL relations, INFLUENZA vaccines, VACCINE effectiveness, HOSPITAL care, OUTPATIENT medical care, HOSPITAL emergency services, DESCRIPTIVE statistics, ODDS ratio, ELECTRONIC health records, INFLUENZA A virus, H3N2 subtype, DATA analysis software, CONFIDENCE intervals, SEASONAL influenza, EVALUATION, ADOLESCENCE, CHILDREN
Abstract

Background During the 2022–2023 influenza season, the United States experienced the highest influenza-associated pediatric hospitalization rate since 2010–2011. Influenza A/H3N2 infections were predominant. Methods We analyzed acute respiratory illness (ARI)–associated emergency department or urgent care (ED/UC) encounters or hospitalizations at 3 health systems among children and adolescents aged 6 months–17 years who had influenza molecular testing during October 2022–March 2023. We estimated influenza A vaccine effectiveness (VE) using a test-negative approach. The odds of vaccination among influenza-A–positive cases and influenza-negative controls were compared after adjusting for confounders and applying inverse-propensity-to-be-vaccinated weights. We developed overall and age-stratified VE models. Results Overall, 13 547 of 44 787 (30.2%) eligible ED/UC encounters and 263 of 1862 (14.1%) hospitalizations were influenza-A–positive cases. Among ED/UC patients, 15.2% of influenza-positive versus 27.1% of influenza-negative patients were vaccinated; VE was 48% (95% confidence interval [CI], 44–52%) overall, 53% (95% CI, 47–58%) among children aged 6 months–4 years, and 38% (95% CI, 30–45%) among those aged 9–17 years. Among hospitalizations, 17.5% of influenza-positive versus 33.4% of influenza-negative patients were vaccinated; VE was 40% (95% CI, 6–61%) overall, 56% (95% CI, 23–75%) among children ages 6 months–4 years, and 46% (95% CI, 2–70%) among those 5–17 years. Conclusions During the 2022–2023 influenza season, vaccination reduced the risk of influenza-associated ED/UC encounters and hospitalizations by almost half (overall VE, 40–48%). Influenza vaccination is a critical tool to prevent moderate-to-severe influenza illness in children and adolescents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Risk of COVID‐19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.

Author

Levy, Matthew E., Yang, Duck‐Hye, Dunne, Margaret M., Miley, Kathleen, Irving, Stephanie A., Grannis, Shaun J., Weber, Zachary A., Griggs, Eric P., Spark, Talia L., Bassett, Elizabeth, Embi, Peter J., Gaglani, Manjusha, Natarajan, Karthik, Valvi, Nimish R., Ong, Toan C., Naleway, Allison L., Stenehjem, Edward, Klein, Nicola P., Link‐Gelles, Ruth, and DeSilva, Malini B.

Abstract

Background: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID‐19 vaccine effectiveness (VE). This study evaluated risk of COVID‐19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status. Methods: In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory‐confirmed COVID‐19‐associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID‐19 vaccination status using Cox proportional hazards regression. Results: Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID‐19‐associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person‐years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18–1.37) and mood (aHR, 1.25; 95% CI, 1.15–1.36), anxiety (aHR, 1.33, 95% CI, 1.22–1.45), and psychotic (aHR, 1.41; 95% CI, 1.14–1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25–0.49) after a recent second dose, 0.08 (95% CI, 0.06–0.11) after a recent third dose, and 0.33 (95% CI, 0.17–0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%). Conclusion: Psychiatric disorders were associated with increased risk of COVID‐19‐associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19—VISION Network, 10 States, June 2021–March 2023.

Author

Griggs, Eric P, Mitchell, Patrick K, Lazariu, Victoria, Gaglani, Manjusha, McEvoy, Charlene, Klein, Nicola P, Valvi, Nimish R, Irving, Stephanie A, Kojima, Noah, Stenehjem, Edward, Crane, Bradley, Rao, Suchitra, Grannis, Shaun J, Embi, Peter J, Kharbanda, Anupam B, Ong, Toan C, Natarajan, Karthik, Dascomb, Kristin, Naleway, Allison L, and Bassett, Elizabeth

Subjects
MORTALITY risk factors, EVALUATION of medical care, INTENSIVE care units, RELATIVE medical risk, COVID-19, IMMUNIZATION, CONFIDENCE intervals, AGE distribution, PATIENTS, CATASTROPHIC illness, RISK assessment, HOSPITAL admission & discharge, HOSPITAL mortality, HOSPITAL care, VACCINATION status, COMORBIDITY, DISEASE complications, EVALUATION
Abstract

Background The epidemiology of coronavirus disease 2019 (COVID-19) continues to develop with emerging variants, expanding population-level immunity, and advances in clinical care. We describe changes in the clinical epidemiology of COVID-19 hospitalizations and risk factors for critical outcomes over time. Methods We included adults aged ≥18 years from 10 states hospitalized with COVID-19 June 2021–March 2023. We evaluated changes in demographics, clinical characteristics, and critical outcomes (intensive care unit admission and/or death) and evaluated critical outcomes risk factors (risk ratios [RRs]), stratified by COVID-19 vaccination status. Results A total of 60 488 COVID-19–associated hospitalizations were included in the analysis. Among those hospitalized, median age increased from 60 to 75 years, proportion vaccinated increased from 18.2% to 70.1%, and critical outcomes declined from 24.8% to 19.4% (all P <.001) between the Delta (June–December, 2021) and post-BA.4/BA.5 (September 2022–March 2023) periods. Hospitalization events with critical outcomes had a higher proportion of ≥4 categories of medical condition categories assessed (32.8%) compared to all hospitalizations (23.0%). Critical outcome risk factors were similar for unvaccinated and vaccinated populations; presence of ≥4 medical condition categories was most strongly associated with risk of critical outcomes regardless of vaccine status (unvaccinated: adjusted RR, 2.27 [95% confidence interval {CI}, 2.14–2.41]; vaccinated: adjusted RR, 1.73 [95% CI, 1.56–1.92]) across periods. Conclusions The proportion of adults hospitalized with COVID-19 who experienced critical outcomes decreased with time, and median patient age increased with time. Multimorbidity was most strongly associated with critical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Vaccine Effectiveness of the Original Monovalent COVID-19 Vaccines in preventing Emergency Department or Urgent Care Encounters and Hospitalizations among Adults with Disabilities: VISION Network, June 2021-September 2022

Author

Patel, Palak, primary, Schrader, Kristin E, additional, Rice, Catherine E, additional, Rowley, Elizabeth, additional, Cree, Robyn A, additional, DeSilva, Malini B, additional, Embi, Peter J, additional, Gaglani, Manjusha, additional, Grannis, Shaun J, additional, Ong, Toan C, additional, Stenehjem, Edward, additional, Naleway, Allison L, additional, Ball, Sarah, additional, Natarajan, Karthik, additional, Klein, Nicola P, additional, Adams, Katherine, additional, Kharbanda, Anupam, additional, Ray, Caitlin, additional, Link-Gelles, Ruth, additional, and Tenforde, Mark W, additional

Published
2023
Full Text
View/download PDF

40. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With Coronavirus Disease 2019—VISION Network, 10 States, June 2021–March 2023

Author

Griggs, Eric P, primary, Mitchell, Patrick K, additional, Lazariu, Victoria, additional, Gaglani, Manjusha, additional, McEvoy, Charlene, additional, Klein, Nicola P, additional, Valvi, Nimish R, additional, Irving, Stephanie A, additional, Kojima, Noah, additional, Stenehjem, Edward, additional, Crane, Bradley, additional, Rao, Suchitra, additional, Grannis, Shaun J, additional, Embi, Peter J, additional, Kharbanda, Anupam B, additional, Ong, Toan C, additional, Natarajan, Karthik, additional, Dascomb, Kristin, additional, Naleway, Allison L, additional, Bassett, Elizabeth, additional, DeSilva, Malini B, additional, Dickerson, Monica, additional, Konatham, Deepika, additional, Fireman, Bruce, additional, Allen, Katie S, additional, Barron, Michelle A, additional, Beaton, Maura, additional, Arndorfer, Julie, additional, Vazquez-Benitez, Gabriela, additional, Garg, Shikha, additional, Murthy, Kempapura, additional, Goddard, Kristin, additional, Dixon, Brian E, additional, Han, Jungmi, additional, Grisel, Nancy, additional, Raiyani, Chandni, additional, Lewis, Ned, additional, Fadel, William F, additional, Stockwell, Melissa S, additional, Mamawala, Mufaddal, additional, Hansen, John, additional, Zerbo, Ousseny, additional, Patel, Palak, additional, Link-Gelles, Ruth, additional, Adams, Katherine, additional, and Tenforde, Mark W, additional

Published
2023
Full Text
View/download PDF

41. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023

Author

Link-Gelles, Ruth, primary, Ciesla, Allison Avrich, additional, Rowley, Elizabeth A.K., additional, Klein, Nicola P., additional, Naleway, Allison L., additional, Payne, Amanda B., additional, Kharbanda, Anupam, additional, Natarajan, Karthik, additional, DeSilva, Malini B., additional, Dascomb, Kristin, additional, Irving, Stephanie A., additional, Zerbo, Ousseny, additional, Reese, Sarah E., additional, Wiegand, Ryan E., additional, Najdowski, Morgan, additional, Ong, Toan C., additional, Rao, Suchitra, additional, Stockwell, Melissa S., additional, Stephens, Ashley, additional, Goddard, Kristin, additional, Martinez, Yessica C., additional, Weber, Zachary A., additional, Fireman, Bruce, additional, Hansen, John, additional, Timbol, Julius, additional, Grannis, Shaun J., additional, Barron, Michelle A., additional, Embi, Peter J., additional, Ball, Sarah W., additional, Gaglani, Manjusha, additional, Grisel, Nancy, additional, Arndorfer, Julie, additional, Tenforde, Mark W., additional, and Fleming-Dutra, Katherine E., additional

Published
2023
Full Text
View/download PDF

42. Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic

Author

Irving, Stephanie A., primary, Crane, Bradley, additional, Weintraub, Eric, additional, Kauffman, Tia L., additional, Brooks, Neon, additional, Patel, Suchita A., additional, Razzaghi, Hilda, additional, Belongia, Edward A., additional, Daley, Matthew F., additional, Getahun, Darios, additional, Glenn, Sungching C., additional, Hambidge, Simon J., additional, Jackson, Lisa A., additional, Kharbanda, Elyse, additional, Klein, Nicola P., additional, Zerbo, Ousseny, additional, and Naleway, Allison L., additional

Published
2023
Full Text
View/download PDF

43. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines

Author

Kenigsberg, Tat'Yana A., primary, Goddard, Kristin, additional, Hanson, Kayla E., additional, Lewis, Ned, additional, Klein, Nicola, additional, Irving, Stephanie A., additional, Naleway, Allison L., additional, Crane, Bradley, additional, Kauffman, Tia L., additional, Xu, Stanley, additional, Daley, Matthew F., additional, Hurley, Laura P., additional, Kaiser, Robyn, additional, Jackson, Lisa A., additional, Jazwa, Amelia, additional, and Weintraub, Eric S., additional

Published
2023
Full Text
View/download PDF

48. Asthma and Farm Exposures in a Cohort of Rural Iowa Children

Author

Merchant, James A., Naleway, Allison L., Svendsen, Erik R., Kelly, Kevin M., Burmeister, Leon F., Stromquist, Ann M., Taylor, Craig D., Thorne, Peter S., Reynolds, Stephen J., Sanderson, Wayne T., and Chrischilles, Elizabeth A.

Published
2005

49. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

Author

Link-Gelles, Ruth, primary, Weber, Zachary A., additional, Reese, Sarah E., additional, Payne, Amanda B., additional, Gaglani, Manjusha, additional, Adams, Katherine, additional, Kharbanda, Anupam B., additional, Natarajan, Karthik, additional, DeSilva, Malini B., additional, Dascomb, Kristin, additional, Irving, Stephanie A., additional, Klein, Nicola P., additional, Grannis, Shaun J., additional, Ong, Toan C., additional, Embi, Peter J., additional, Dunne, Margaret M., additional, Dickerson, Monica, additional, McEvoy, Charlene, additional, Arndorfer, Julie, additional, Naleway, Allison L., additional, Goddard, Kristin, additional, Dixon, Brian E., additional, Griggs, Eric P., additional, Hansen, John, additional, Valvi, Nimish, additional, Najdowski, Morgan, additional, Timbol, Julius, additional, Rogerson, Colin, additional, Fireman, Bruce, additional, Fadel, William F., additional, Patel, Palak, additional, Ray, Caitlin S., additional, Wiegand, Ryan, additional, Ball, Sarah, additional, and Tenforde, Mark W., additional

Published
2023
Full Text
View/download PDF

50. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design

Author

Babu, Tara M, primary, Feldstein, Leora R, additional, Saydah, Sharon, additional, Acker, Zachary, additional, Boisvert, Cassandra L, additional, Briggs-Hagen, Melissa, additional, Carone, Marco, additional, Casto, Amanda, additional, Cox, Sarah N, additional, Ehmen, Brenna, additional, Englund, Janet A, additional, Fortmann, Stephen P, additional, Frivold, Collrane J, additional, Groom, Holly, additional, Han, Peter D, additional, Kuntz, Jennifer L, additional, Lockwood, Tina, additional, Midgley, Claire M, additional, Mularski, Richard A, additional, Ogilvie, Tara, additional, Reich, Sacha L, additional, Schmidt, Mark A, additional, Smith, Ning, additional, Starita, Lea, additional, Stone, Jeremy, additional, Vandermeer, Meredith, additional, Weil, Ana A, additional, Wolf, Caitlin R, additional, Chu, Helen Y, additional, and Naleway, Allison L, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results